All In MedTech

Device Trial Radar · NCT05796453

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

Long-term Evaluation of Safety and Performance of Clareon Presbyopia-Correcting Intraocular Lenses (IOLs)

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

470

Actual

Start

Sep 19, 2023

Primary completion

Aug 21, 2026

Study completion Aug 21, 2026

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Apr 3, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.

Conditions

  • Aphakia
  • Astigmatism
  • Presbyopia

Interventions

  • Clareon Vivity IOL - Non ToricDevice

    Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.

  • Clareon Vivity IOL - ToricDevice

    Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.

  • Clareon PanOptix Trifocal IOL - Non ToricDevice

    Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.

  • Clareon PanOptix Trifocal IOL - ToricDevice

    Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) at each prospective visitTime frame: Up to Year 3
  2. Number of Adverse EventsTime frame: Up to Year 3
  3. Number of Device DeficienciesTime frame: Up to Year 3

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Wolstan & Goldberg Eye Associates

    Torrance, California

  • Levenson Eye Associates

    Jacksonville, Florida

  • Eye Surgeons of CNY

    Liverpool, New York

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.